BioNexus Gene Lab Corp Common stock (BGLC) — Cash Flow-to-Debt Ratio
BioNexus Gene Lab Corp Common stock (BGLC) has a Cash Flow-to-Debt Ratio of -1.53x as of September 2025, meaning its operating cash flow of $-1.23 Million could theoretically repay -2% of its total liabilities ($804.97K) in one year. See BGLC FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
BioNexus Gene Lab Corp Common stock Cash Flow-to-Debt Ratio (2016–2024)
Historical debt coverage capacity for BioNexus Gene Lab Corp Common stock across 9 annual periods. For the full cash flow conversion analysis, see cash flow conversion of BioNexus Gene Lab Corp Common stock.
Annual Cash Flow-to-Debt Ratio for BioNexus Gene Lab Corp Common stock (2016–2024)
Year-by-year debt coverage analysis for BioNexus Gene Lab Corp Common stock. Check BioNexus Gene Lab Corp Common stock (BGLC) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.06x | $-2.23 Million | $2.11 Million | ▼ -4.7% |
| 2023 | -1.01x | $-1.76 Million | $1.74 Million | ▼ -485.6% |
| 2022 | 0.26x | $544.03K | $2.08 Million | ▲ +6752.7% |
| 2021 | 0.00x | $9.16K | $2.39 Million | ▼ -97.6% |
| 2020 | 0.16x | $552.68K | $3.45 Million | ▲ +108.0% |
| 2019 | -2.00x | $-217.27K | $108.87K | ▲ +5.1% |
| 2018 | -2.10x | $-274.08K | $130.31K | ▼ -793.7% |
| 2017 | 0.30x | $357.22K | $1.18 Million | ▲ +148.5% |
| 2016 | -0.62x | $-835.00 | $1.34K | — |